All news

Delphi advisor to Immunicum AB (publ) in connection with rights issue

Delphi has acted as legal advisor to Immunicum AB (publ) (“Immunicum”) in connection with a rights issue of approximately SEK 111 million and an over-allotment option of approximately SEK 17 million.

 

Immunicum develops cancer immunotherapies for the treatment of tumor diseases. Immunicum aims to advance therapeutic cancer treatments at least through clinical phase II trials and then license the product candidates to major pharmaceutical or biotech companies. Immunicum is listed on Nasdaq First North Premier.

The issue will allow Immunicum to expand their ongoing clinical phase II trial in renal cancer and to initiate additional clinical phase I/II trials in melanoma.

Redeye has acted as financial advisor to Immunicum.

Delphi’s team consisted of responsible partner Mats Dahlberg and Jonas Ingvarson, Emma Dansbo, Sandra Lima and Linn Eriksson.